Pseudomonas aeruginosa enfeksiyonlarında optimize edilmiş piperasilin-tazobaktam dozlamasının klinik sonuçları: Öncesi-sonrası kohort çalışması
ESCP, Lisbon, Portekiz, 12 - 14 Ekim 2026, ss.1, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Basıldığı Şehir: Lisbon
- Basıldığı Ülke: Portekiz
- Sayfa Sayıları: ss.1
- Marmara Üniversitesi Adresli: Evet
Özet
BACKGROUND:
Pseudomonas
aeruginosa is one
of the leading pathogens for deaths attributed to resistance
AIM:
This study aimed to evaluate the clinical benefits of a loading
dose followed by extended infusion of piperasilin tazobactam in patients with
P.aeruginosa isolated from blood or sputum cultures,
highlighting the collaborative role of infectious disease specialists and
clinical pharmacists in optimizing antimicrobial therapy.
METHOD:
This
study consisted of two consecutived 3 month periods. In the retrospective (control)
period, patients with P. aeruginosa growth received
piperacillin-tazobactam via traditional infusion. In the subsequent prospective
period, an optimized dosing protocol designed through multidisciplinary
collaboration was implemented, where patients received a loading dose followed
by an extended infusion. Patients requiring escalation/de-escalation therapy or
those with P. aeruginosa isolated from cultures other than blood or
sputum were excluded.
RESULTS:
Each
study period lasted 3 months. A total of 47 patients were assessed for
eligibility, including 25 patients in the retrospective cohort and 22 in the
prospective cohort. Following exclusions due to additional microbial growth
(n=4) and adverse events (n=3), 40 patients were included in the final analysis
(20 per group). The median age of the study population was 66 years, and 60.4%
were male. There were no significant differences between the groups in Charlson
Comorbidity Index scores (median 4 vs 5, p = 0.4; Mann–Whitney U test).
Clinical non-response occurred in 2 of 20 patients (10%) in the prospective
group and 9 of 20 patients (45%) in the retrospective group, representing a
statistically significant reduction in the prospective cohort (Fisher’s exact
test, p = 0.03). Linear regression analysis demonstrated that the cost
model was statistically significant, F(2, 37) = 28.68, p < 0.001, and
explained 60.79% of the variance in cost (R² = 0.608)
CONCLUSION:
Implementing
a loading dose followed by an extended infusion protocol significantly improves
clinical response rates in severe P. aeruginosa infections. These
findings underscore the critical value of joint interventions between
infectious disease physicians and clinical pharmacists in translating pharmacokinetics/
pharmacodynamics principles into bedside practice, ultimately optimizing
treatment outcomes against high-risk resistant pathogens.